Literature DB >> 28600384

Oxetane Substrates of Human Microsomal Epoxide Hydrolase.

Francesca Toselli1, Marlene Fredenwall1, Peder Svensson1, Xue-Qing Li1, Anders Johansson1, Lars Weidolf1, Martin A Hayes2.   

Abstract

Oxetanyl building blocks are increasingly used in drug discovery because of the improved drug-like properties they confer on drug candidates, yet little is currently known about their biotransformation. A series of oxetane-containing analogs was studied and we provide the first direct evidence of oxetane hydrolysis by human recombinant microsomal epoxide hydrolase (mEH). Incubations with human liver fractions and hepatocytes were performed with and without inhibitors of cytochrome P450 (P450), mEH and soluble epoxide hydrolase (sEH). Reaction dependence on NADPH was investigated in subcellular fractions. A full kinetic characterization of oxetane hydrolysis is presented, in both human liver microsomes and human recombinant mEH. In human liver fractions and hepatocytes, hydrolysis by mEH was the only oxetane ring-opening metabolic route, with no contribution from sEH or from cytochrome P450-catalyzed oxidation. Minimally altering the structural elements in the immediate vicinity of the oxetane can greatly modulate the efficiency of hydrolytic ring cleavage. In particular, higher pKa in the vicinity of the oxetane and an increased distance between the oxetane ring and the benzylic nitrogen improve reaction rate, which is further enhanced by the presence of methyl groups near or on the oxetane. This work defines oxetanes as the first nonepoxide class of substrates for human mEH, which was previously known to catalyze the hydrolytic ring opening of electrophilic and potentially toxic epoxide-containing drugs, drug metabolites, and exogenous organochemicals. These findings will be of value for the development of biologically active oxetanes and may be exploited for the biocatalytic generation of enantiomerically pure oxetanes and diols.
Copyright © 2017 by The American Society for Pharmacology and Experimental Therapeutics.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28600384     DOI: 10.1124/dmd.117.076489

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  3 in total

1.  When Cofactors Aren't X Factors: Functional Groups That Are Labile in Human Liver Microsomes in the Absence of NADPH.

Authors:  Matthew L Landry; Richard Trager; Fabio Broccatelli; James J Crawford
Journal:  ACS Med Chem Lett       Date:  2022-03-11       Impact factor: 4.632

2.  Development of potent inhibitors of the human microsomal epoxide hydrolase.

Authors:  Bogdan Barnych; Nalin Singh; Sophie Negrel; Yue Zhang; Damien Magis; Capucine Roux; Xiude Hua; Zhewen Ding; Christophe Morisseau; Dean J Tantillo; Justin B Siegel; Bruce D Hammock
Journal:  Eur J Med Chem       Date:  2020-03-13       Impact factor: 6.514

Review 3.  Put a ring on it: application of small aliphatic rings in medicinal chemistry.

Authors:  Matthias R Bauer; Paolo Di Fruscia; Simon C C Lucas; Iacovos N Michaelides; Jennifer E Nelson; R Ian Storer; Benjamin C Whitehurst
Journal:  RSC Med Chem       Date:  2021-01-07
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.